The impact of extracorporeal membrane oxygenation on mortality in patients with cardiogenic shock post acute myocardial infarction: a systematic review and meta-analysis

S. Paddock, James Meng, Nicholas Johnson, Rahul Chattopadhyay, V. Tsampasian, V. Vassiliou
{"title":"The impact of extracorporeal membrane oxygenation on mortality in patients with cardiogenic shock post acute myocardial infarction: a systematic review and meta-analysis","authors":"S. Paddock, James Meng, Nicholas Johnson, Rahul Chattopadhyay, V. Tsampasian, V. Vassiliou","doi":"10.1093/ehjopen/oeae003","DOIUrl":null,"url":null,"abstract":"\n \n \n Cardiogenic shock remains the leading cause of death in patients hospitalised with acute myocardial infarction. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used in the treatment of infarct-related cardiogenic shock. However, there is limited evidence regarding its beneficial impact on mortality.\n \n \n \n To systematically review studies reporting the impact of VA-ECMO on mortality in patients with acute myocardial infarction complicated by cardiogenic shock.\n \n \n \n Comprehensive search of medical databases (Cochrane Register, PubMed) was conducted. Studies that reported mortality outcomes in patients treated with VA-ECMO for infarct-related cardiogenic shock were included.\n \n \n \n The database search yielded 1194 results, of which 11 studies were included in the systematic review. Four of these studies, with a total of 586 patients, were randomised-controlled trials and were included in the meta-analysis. This demonstrated that there was no significant difference in 30-day all-cause mortality with the use of VA-ECMO compared to standard medical therapy (OR 0.91; 95% confidence interval (CI) 0.65-1.27). Meta-analysis of two studies showed that VA-ECMO was associated with a significant reduction in 12-month all-cause mortality (OR 0.31, CI 0.11-0.86). Qualitative synthesis of the observational studies showed that age, serum creatinine, serum lactate and successful revascularisation are independent predictors of mortality.\n \n \n \n VA-ECMO does not improve 30-day all-cause mortality in patients with cardiogenic shock following acute myocardial infarction, however there may be significant reduction in all-cause mortality at 12 months. Further studies are needed to delineate the potential benefit of VA-ECMO in long-term outcomes.\n \n \n \n The protocol was registered in the PROSPERO International Prospective Register of Systematic Reviews (ID: CRD42023461740).\n","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"76 13","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European heart journal open","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.1093/ehjopen/oeae003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Cardiogenic shock remains the leading cause of death in patients hospitalised with acute myocardial infarction. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used in the treatment of infarct-related cardiogenic shock. However, there is limited evidence regarding its beneficial impact on mortality. To systematically review studies reporting the impact of VA-ECMO on mortality in patients with acute myocardial infarction complicated by cardiogenic shock. Comprehensive search of medical databases (Cochrane Register, PubMed) was conducted. Studies that reported mortality outcomes in patients treated with VA-ECMO for infarct-related cardiogenic shock were included. The database search yielded 1194 results, of which 11 studies were included in the systematic review. Four of these studies, with a total of 586 patients, were randomised-controlled trials and were included in the meta-analysis. This demonstrated that there was no significant difference in 30-day all-cause mortality with the use of VA-ECMO compared to standard medical therapy (OR 0.91; 95% confidence interval (CI) 0.65-1.27). Meta-analysis of two studies showed that VA-ECMO was associated with a significant reduction in 12-month all-cause mortality (OR 0.31, CI 0.11-0.86). Qualitative synthesis of the observational studies showed that age, serum creatinine, serum lactate and successful revascularisation are independent predictors of mortality. VA-ECMO does not improve 30-day all-cause mortality in patients with cardiogenic shock following acute myocardial infarction, however there may be significant reduction in all-cause mortality at 12 months. Further studies are needed to delineate the potential benefit of VA-ECMO in long-term outcomes. The protocol was registered in the PROSPERO International Prospective Register of Systematic Reviews (ID: CRD42023461740).
体外膜氧合对急性心肌梗死后心源性休克患者死亡率的影响:系统回顾和荟萃分析
心源性休克仍是急性心肌梗死住院患者的主要死因。静脉-动脉体外膜肺氧合(VA-ECMO)越来越多地被用于治疗与心肌梗死相关的心源性休克。然而,有关其对死亡率有益影响的证据却很有限。 系统回顾有关 VA-ECMO 对急性心肌梗死并发心源性休克患者死亡率影响的研究报告。 对医学数据库(Cochrane Register、PubMed)进行了全面检索。纳入了报告了接受 VA-ECMO 治疗的心肌梗死相关心源性休克患者死亡率结果的研究。 数据库搜索共获得 1194 项结果,其中 11 项研究被纳入系统综述。其中四项研究是随机对照试验,纳入了荟萃分析,共涉及 586 名患者。结果表明,与标准药物治疗相比,使用 VA-ECMO 的 30 天全因死亡率没有明显差异(OR 0.91;95% 置信区间 (CI) 0.65-1.27)。两项研究的 Meta 分析表明,VA-ECMO 可显著降低 12 个月的全因死亡率(OR 0.31,CI 0.11-0.86)。观察性研究的定性综合显示,年龄、血清肌酐、血清乳酸和成功的血管再通是预测死亡率的独立因素。 VA-ECMO不能改善急性心肌梗死后心源性休克患者的30天全因死亡率,但12个月后全因死亡率可能会显著降低。要确定VA-ECMO对长期预后的潜在益处,还需要进一步的研究。 该研究方案已在 PROSPERO 国际前瞻性系统综述注册中心注册(ID:CRD42023461740)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信